EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 170 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2020 | $1,763,000 | +6.9% | 36,747 | +2.5% | 0.01% | -12.5% |
Q1 2020 | $1,649,000 | -23.2% | 35,837 | +0.2% | 0.01% | 0.0% |
Q4 2019 | $2,148,000 | +20.0% | 35,749 | +13.0% | 0.01% | +14.3% |
Q3 2019 | $1,790,000 | +5.6% | 31,642 | +4.0% | 0.01% | 0.0% |
Q2 2019 | $1,695,000 | +4.6% | 30,432 | -5.2% | 0.01% | -22.2% |
Q1 2019 | $1,620,000 | +17.7% | 32,085 | -6.1% | 0.01% | 0.0% |
Q4 2018 | $1,376,000 | -40.7% | 34,164 | -0.3% | 0.01% | -40.0% |
Q3 2018 | $2,320,000 | -9.2% | 34,251 | +1.4% | 0.02% | -11.8% |
Q2 2018 | $2,554,000 | +43.7% | 33,762 | +0.1% | 0.02% | +30.8% |
Q1 2018 | $1,777,000 | -1.1% | 33,718 | +0.3% | 0.01% | 0.0% |
Q4 2017 | $1,796,000 | -10.7% | 33,613 | -0.3% | 0.01% | -13.3% |
Q3 2017 | $2,011,000 | -24.8% | 33,717 | -0.5% | 0.02% | -28.6% |
Q2 2017 | $2,673,000 | -5.1% | 33,887 | -0.3% | 0.02% | -8.7% |
Q1 2017 | $2,818,000 | +5.9% | 33,973 | +1.3% | 0.02% | 0.0% |
Q4 2016 | $2,660,000 | – | 33,522 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Hudson Executive Capital LP | 1,323,794 | $79,534,000 | 3.54% |
Park West Asset Management LLC | 1,171,880 | $70,406,000 | 2.96% |
Matarin Capital Management, LLC | 170,008 | $10,214,000 | 0.98% |
Smith, Graham & Co., Investment Advisors, LP | 140,014 | $8,412,000 | 0.82% |
Capital Impact Advisors, LLC | 33,725 | $2,026,000 | 0.71% |
U S GLOBAL INVESTORS INC | 18,800 | $1,130,000 | 0.51% |
CHARTWELL INVESTMENT PARTNERS, LLC | 187,989 | $11,294,000 | 0.37% |
Stanley-Laman Group, Ltd. | 24,000 | $1,442,000 | 0.34% |
GLOBEFLEX CAPITAL L P | 18,751 | $1,127,000 | 0.21% |
Foundry Partners, LLC | 70,357 | $4,227,000 | 0.16% |